Miraculins Announces Private Placement Offering

Miraculins Inc. (TSX VENTURE:MOM) (the "Company"), a medical diagnostic company
focused on acquiring, developing and commercializing diagnostic tests and risk
assessment technologies for unmet clinical needs, today announces a non-brokered
private placement offering (the "Offering") of up to 2,272,727 units ("Units")
at a price of $0.11 per Unit for gross proceeds of up to $250,000. Each Unit
will be comprised of one common share of the Company (a "Share") and one Share
purchase warrant. Each whole warrant (a "Warrant") will entitle the holder to
purchase one Share at a price of $0.15 per Share for a period of 12 months from
the date the Warrant is issued.


Certain persons may assist the Company by introducing potential subscribers for
the Offering and, subject to compliance with applicable legislation, will be
entitled to receive a finder's fee, payable in cash and share purchase warrants,
as permitted by law.


The net proceeds of the Offering will be used for general corporate purposes.

The Offering is subject to receipt of all necessary approvals, including the
approval of the TSX Venture Exchange.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Christopher J. Moreau
President & CEO
Miraculins Inc.
204-477-7599
204-453-1546 (FAX)
[e-mail]
www.miraculins.com